Deficiency of the type I interferon receptor protects mice from experimental lupus
Open Access
- 29 October 2007
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (11) , 3770-3783
- https://doi.org/10.1002/art.23023
Abstract
Objective Systemic lupus erythematosus (SLE) is diagnosed according to a spectrum of clinical manifestations and autoantibodies associated with abnormal expression of type I interferon (IFN‐I)–stimulated genes (ISGs). The role of IFN‐I in the pathogenesis of SLE remains uncertain, partly due to the lack of suitable animal models. The objective of this study was to examine the role of IFN‐I signaling in the pathogenesis of murine lupus induced by 2,6,10,14‐tetramethylpentadecane (TMPD). Methods IFN‐I receptor–deficient (IFNAR−/−) 129Sv mice and wild‐type (WT) 129Sv control mice were treated intraperitoneally with TMPD. The expression of ISGs was measured by real‐time polymerase chain reaction. Autoantibody production was evaluated by immunofluorescence and enzyme‐linked immunosorbent assay. Proteinuria and renal glomerular cellularity were measured and renal immune complexes were examined by immunofluorescence. Results Increased ISG expression was observed in the peripheral blood of TMPD‐treated WT mice, but not in the peripheral blood of TMPD‐treated IFNAR−/− mice. TMPD did not induce lupus‐specific autoantibodies (anti‐RNP, anti‐Sm, anti–double‐stranded DNA) in IFNAR−/− mice, whereas 129Sv controls developed these specificities. Although glomerular immune complexes were present in IFNAR−/− mice, proteinuria and glomerular hypercellularity did not develop, whereas these features of glomerulonephritis were found in the TMPD‐treated WT controls. The clinical and serologic manifestations observed in TMPD‐treated mice were strongly dependent on IFNAR signaling, which is consistent with the association of increased expression of ISGs with lupus‐specific autoantibodies and nephritis in humans. Conclusion Similar to its proposed role in human SLE, signaling via the IFNAR is central to the pathogenesis of autoantibodies and glomerulonephritis in TMPD‐induced lupus. This lupus model is the first animal model shown to recapitulate the “interferon signature” in peripheral blood.Keywords
This publication has 49 references indexed in Scilit:
- Elevated Serum Levels of Interferon-Regulated Chemokines Are Biomarkers for Active Human Systemic Lupus ErythematosusPLoS Medicine, 2006
- Autoreactive B Cell Responses to RNA-Related Antigens Due to TLR7 Gene DuplicationScience, 2006
- Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosusClinical Immunology, 2005
- Type I interferon dependence of plasmacytoid dendritic cell activation and migrationThe Journal of Experimental Medicine, 2005
- Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB MiceThe Journal of Experimental Medicine, 2003
- Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus BloodThe Journal of Experimental Medicine, 2003
- DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology, 2002
- Functional Role of Type I and Type II Interferons in Antiviral DefenseScience, 1994
- Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation.Journal of Clinical Investigation, 1991
- Pristane‐induced arthritis. the immunologic and genetic features of an experimental murine model of autoimmune diseaseArthritis & Rheumatism, 1989